ArticleNature medicine2018
Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis.
Erratum issuedAbstract read
In one paragraph
Article in Nature medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 664 papers.
0numbers the graph read from it
0cells of the map it votes in
664citing papers in PubMed
38.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
664 citing papers in PubMed, 971 citations in OpenAlex.
- Temporal and spatial composition of the tumor microenvironment predicts response to immune checkpoint inhibition in metastatic TNBC.Nature cancer · 2026Trial
- A Phase II Pilot Study of Anti-PD-L1, Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple-Negative Breast Cancer With or Without Germline BRCA Mutation.Cancer medicine · 2025Trial
- Palbociclib and endocrine therapy diminish adaptive anti-tumor immunity in early breast cancer: The NeoRHEA phase 2 study.Nature communications · 2025Trial
- Distinct CD8Cancer cell · 2025Trial
- Oncolytic adenovirus in treating malignant ascites: A phase II trial and longitudinal single-cell study.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Trial
- scGEN: Leveraging an Adaptive Weighting Strategy for Challenging Cell Clustering in Single-Cell RNA-seq.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- UBE2A as a prognostic indicator across human cancers: Insights from multi‑omics and immune landscape analyses.Molecular medicine reports · 2026Article
- Article
- CD39 on CD8European journal of immunology · 2026Review
- Artificial intelligence-based tumour infiltrating lymphocyte quantification in patients with triple-negative breast cancer: an independent validation study.The Lancet. Oncology · 2026Article
- GermlineImmuno-oncology technology · 2026Article
- Integrating zero-inflation correction and transcriptional kinetics for single-cell transcriptomic analysis.PLoS computational biology · 2026Article
- Article
- Current and future therapies for triple-negative breast cancer.Journal of hematology & oncology · 2026Review
- scRNA-Seq in Gastric Cancer Reveals Macrophage-Derived C1q as a Diagnostic Marker.Cancer science · 2026Article
- PRDM15 inhibits responses of Tissue-Resident memory T cells by activating PVR/TIGIT axis to mediate gastric cancer immunosuppression.Journal of advanced research · 2026Article
- Pregnancy-induced tissue-resident memory-like T cells contribute to tumor control in breast cancer.Nature immunology · 2026Article
- TLS as Predictors and Targets in Neoadjuvant Chemoimmunotherapy for NSCLC.Thoracic cancer · 2026Review
- The initial melanoma T cell infiltrate is defined by tissue-resident programs restrained by regulatory T cells.Research square · 2026Article
- Spatial organization of the TNBC tumor microenvironment: multicellular niches, T-cell bottlenecks, and therapeutic opportunities.Journal of translational medicine · 2026Review
604 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
26 authors at 4 institutions in 3 countries.
Peter SavasDivision of Research, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0001-5999-428X
Balaji VirassamyDivision of Research, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.
Chengzhong YeBioinformatics Division, Walter & Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
Agus SalimBioinformatics Division, Walter & Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
Christopher P MintoffDivision of Research, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.
Franco CaramiaDivision of Research, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.
Roberto SalgadoDivision of Research, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.
David J ByrneDepartment of Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Zhi L TeoDivision of Research, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.
Sathana DushyanthenDivision of Research, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.
Ann ByrneDivision of Research, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.
Lironne WeinDivision of Research, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.
Stephen J LuenDivision of Research, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.
Catherine PolinessDivision of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sophie S NightingaleDivision of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Anita S SkandarajahDivision of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
David E GyorkiDivision of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Chantel M ThorntonDivision of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Paul A BeavisDivision of Research, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.
Stephen B FoxSir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0002-7648-8896
Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab)
Phillip K DarcyDivision of Research, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.
Terence P SpeedBioinformatics Division, Walter & Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
Laura K MackayDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0002-8496-6632
Paul J NeesonDivision of Research, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia. paul.neeson@petermac.org.
Sherene LoiDivision of Research, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia. sherene.loi@petermac.org.ORCID http://orcid.org/0000-0001-6137-9171
The University of Melbourne · AUPeter MacCallum Cancer Centre · AUThe Royal Melbourne Hospital · AUWalter and Eliza Hall Institute of Medical Research · AU
Funding
No grant is acknowledged in the PubMed record.
Abstract
The quantity of tumor-infiltrating lymphocytes (TILs) in breast cancer (BC) is a robust prognostic factor for improved patient survival, particularly in triple-negative and HER2-overexpressing BC subtypes
Indexed as
Immunologic MemoryBreast NeoplasmsCD3 ComplexCD8 AntigensDisease-Free SurvivalFemaleHumansKaplan-Meier EstimateLymphocytes, Tumor-InfiltratingPrognosisSequence Analysis, RNASingle-Cell AnalysisTriple Negative Breast NeoplasmsCD3 ComplexCD8 Antigens
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.